Dear Editor, We would like to report the pharmacokinetics (PK) of caspofungin in a critically ill patient with Child B9 liver cirrhosis. Caspofungin is the first echinocandin approved for the treatment of invasive fungal infections caused by Candida and Aspergillus spp [1] . Because it is generally well tolerated and appears to have limited interaction with other drugs, caspofungin is potentially an important agent in the treatment of invasive fungal infections in critically ill patients, especially in those not tolerating treatment with voriconazole due to severe liver insufficiency [1] .
Case history
A 53-year-old man (85 kg) was admitted to the intensive care unit (ICU) of our hospital because of respiratory failure and septic shock due to spontaneous bacterial peritonitis. He had a past medical history of alcoholic liver cirrhosis (Child-Pugh score B9) and had been recently diagnosed with acute myeloid leukemia (AML-M2). Three weeks prior to admission he was treated with high-dose cytarabine. On admission, physical examination revealed high fever, low blood pressure, ascites and acute respiratory failure. Blood analysis showed neutropenia, acute renal failure and high C-reactive protein level. Liver function tests revealed a total bilirubin level of 3.54 mg/dL (normal <1 mg/dL), aspartate transaminase level of 104 U/L (normal <32 U/L) and alanine transaminase level of 140 U/L (normal <31 U/L). He required orotracheal intubation, mechanical ventilation, administration of vasopressors and renal replacement therapy. A chest X-ray showed signs of pneumonia. Meropenem 1 g once daily was administered as empiric therapy.
A progressively increasing serum Aspergillus antigen level and lesions visible on a computed tomography (CT) scan of the chest were compatible with a diagnosis of invasive pulmonary aspergillosis for which treatment was started with caspofungin. Given the poor prognosis of invasive aspergillosis and the good safety profile of caspofungin, a full dose of 70 mg once daily was chosen as the treatment regimen, as required for patients with a body weight >80 kg, in contrast to a reduced dose recommended in patients with moderate liver cirrhosis [2] .
Caspofungin steady-state trough (C 24h ) and peak (C 1h ) plasma levels were determined on days 13 and 14 of treatment using a previously validated high-performance liquid chromatography-ultraviolet method [3] . Troughs and peaks were 3.81 and 3.88 mg/L and 8.01 and 9.07 mg/L, respectively, on days 13 and 14. PK parameters were calculated on the mean trough and peak levels as described previously and shown in Table 1 [3] . The patient's liver function tests remained stable during the treatment with caspofungin, and the serum Aspergillus antigen gradually decreased, which was interpreted as a good antifungal response without systemic toxicity. The lesions on the chest X-ray improved as well.
Discussion
The recommended dose for treating invasive fungal infections is 70 mg on day 1 followed by a maintenance dose of 50 mg/day [1] . However, a dose reduction to 35 mg daily following the 70 mg loading dose is recommended for patients with moderate hepatic insufficiency (Child-Pugh score B7-9), as the area under the curve (AUC 0-24 ) of caspofungin is significantly increased in this population [1, 4] . The phase I PK studies addressing dosing recommendations in patients with hepatic insufficiency were however undertaken in patients with chronic and stable hepatic insufficiency, without acute episodes of illnesses [4] . There are as yet no data available on the PK of caspofungin in critically ill, mechanically ventilated patients with underlying liver cirrhosis.
We compared the PK parameters calculated for our patient to those calculated after single and multiple doses of 70 mg in healthy subjects, to trough levels described in 40 surgical ICU patients and to the PK parameters calculated after multiple dosing in patients with moderate liver failure [4] [5] [6] . The results of this comparison are shown in Table 1 . The AUC 0-24 is comparable to that reported in healthy subjects; accumulation due to decreased hepatic metabolism resulting in a significantly higher systemic exposure (C 1h , C 24h , AUC 0-24 ) was not observed. Moreover, it would appear that using a standard dose of caspofungin in severely ill patients with underlying moderate liver disease is likely needed to avoid underdosing. Reducing the dose in our patient, as recommended for patients with Child-Pugh score B7-9 liver failure, would probably have resulted in a too low caspofungin systemic exposure and therapeutic failure. Possible explanations for this result are PK alterations typically seen in ICU patients, such as capillary leak due to sepsis, leading to a higher distribution, volume or lower albumin levels, leading to a more rapid elimination by the kidney or hemodialysis.
In critically ill patients with life-threatening invasive fungal infections, the benefits and risks of adjusting the caspofungin dose in accordance to the recommendations for patients with chronic liver failure have to be carefully assessed. Therapeutic drug monitoring can potentially assist in these particular situations in preventing drug-related toxicity or underdosing leading to therapeutic failure. 
